Sheila Gujrathi - 29 Feb 2024 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Director
Signature
/s/ Maria Dobek, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
29 Feb 2024
Net transactions value
$0
Form type
4
Filing time
04 Mar 2024, 16:44:32 UTC
Previous filing
23 Jan 2024
Next filing
07 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JANX Common Stock Other $0 +2,986 +2.8% $0.000000 108,028 29 Feb 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents receipt of securities in a pro rata, in-kind distribution, and not a purchase of securities, by ABV SPV I GP LLC, of which Reporting Person is a member.